GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Amneal Pharmaceuticals AMRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

21.12

-1.26%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Amneal Pharmaceuticals — daily AMRX Delayed
Market value
$6.86bn
Last close × shares
Volume
1.7m
Shares, 20 Nov 2026
Price to earnings
50.6

About Amneal Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Its shares trade on Nasdaq under the ticker AMRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $3.02bn and net income of $72.1m. At that date it held total assets of $3.68bn and shareholders' equity of −$70.8m.

In its own words

Although we had a minority economic interest in Amneal prior to March 2023, we were Amneal’s sole managing member (and we continue to be the sole managing member), having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, we consolidated the financial statements of Amneal and its subsidiaries for all periods prior to the Reorganization. We recorded non-controlling interests for the portion of Amneal’s economic interests that we did not hold prior to the Reorganization.

On May 8, 2025, we entered into a 15-year strategic collaboration agreement with ApiJect Systems, Corp. and related entities (“ApiJect”), a medical technology company focused on advanced drug delivery (“ApiJect Agreement”). Under the ApiJect Agreement, we will install and operate manufacturing equipment leased from Apiject at our Brookhaven, New York facility. This equipment will be used to support production of ApiJect’s proprietary blow fill seal (“BFS”) delivery systems and our growing injectable portfolio. We will pay a low-digit royalty to ApiJect for any of our commercial products that are manufactured utilizing the equipment. At the conclusion of the term of the ApiJect Agreement, we have the right to purchase the equipment from ApiJect for a nominal amount. We will also collaborate with ApiJect on the development of additional injectable product programs utilizing ApiJect’s BFS platform. We are entitled to receive consideration from ApiJect for development work performed under these programs.

Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗

More about Amneal Pharmaceuticals →

How it makes its money

Revenue, year to 31 Dec 2025

  • Subtotal dosage forms $1.73bn · 57.4%
  • Oral solid $726.4m · 24.1%
  • Subtotal therapeutic classes $528.0m · 17.5%
  • Distribution $408.5m · 13.5%

Latest on Amneal Pharmaceuticals

Our reporting

We have not reported on Amneal Pharmaceuticals yet.

Next results

26 Feb 2027

Due on 26 Feb 2027. Analysts expect earnings of 0.24 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Amneal Pharmaceuticals's ticker?

Amneal Pharmaceuticals trades as AMRX on its US listing, under ISIN US03168L1052.

What was Amneal Pharmaceuticals's last closing price?

21.12 on 20 Nov 2026. The figure is in USD and is never converted.

When does Amneal Pharmaceuticals next report results?

Results are expected on 26 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.